HeartBeam shares are trading higher after the company announced completion of patient enrollment in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection.

Benzinga Newsdesk www.benzinga.com Positive 94.5%

Neg 0% Neu 0% Pos 94.5%

Comments

No comments yet. Be the first!